150 related articles for article (PubMed ID: 16484767)
1. Inhaled ethanolic and aqueous solutions via Respimat Soft Mist Inhaler are well-tolerated in asthma patients.
Patel KR; Pavia D; Lowe L; Spiteri M
Respiration; 2006; 73(4):434-40. PubMed ID: 16484767
[TBL] [Abstract][Full Text] [Related]
2. Acute local tolerability of acidic aqueous vehicles delivered via Respimat Soft Mist Inhaler in hyperreactive asthma patients.
Leclerc V; Lafferre M; Pavia D
Respiration; 2007; 74(6):691-6. PubMed ID: 17728532
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat Soft Mist inhaler: results of phase II single-dose crossover studies.
Koehler D; Pavia D; Dewberry H; Hodder R
Respiration; 2004; 71(5):469-76. PubMed ID: 15467324
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.
von Berg A; Jeena PM; Soemantri PA; Vertruyen A; Schmidt P; Gerken F; Razzouk H
Pediatr Pulmonol; 2004 Mar; 37(3):264-72. PubMed ID: 14966821
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary function response to EDTA, an additive in nebulized bronchodilators.
Asmus MJ; Barros MD; Liang J; Chesrown SE; Hendeles L
J Allergy Clin Immunol; 2001 Jan; 107(1):68-72. PubMed ID: 11149993
[TBL] [Abstract][Full Text] [Related]
9. A review of the development of Respimat Soft Mist Inhaler.
Dalby R; Spallek M; Voshaar T
Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
[TBL] [Abstract][Full Text] [Related]
10. Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients.
van Noord JA; Smeets JJ; Creemers JP; Greefhorst LP; Dewberry H; Cornelissen PJ
Respiration; 2000; 67(6):672-8. PubMed ID: 11124651
[TBL] [Abstract][Full Text] [Related]
11. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients.
Kunkel G; Magnussen H; Bergmann K; Juergens UR; de Mey C; Freund E; Hinzmann R; Beckers B
Respiration; 2000; 67(3):306-14. PubMed ID: 10867600
[TBL] [Abstract][Full Text] [Related]
12. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
Kilfeather SA; Ponitz HH; Beck E; Schmidt P; Lee A; Bowen I; Hesse Ch
Respir Med; 2004 May; 98(5):387-97. PubMed ID: 15139567
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
14. Studies of the effects of inhaled magnesium on airway reactivity to histamine and adenosine monophosphate in asthmatic subjects.
Hill J; Lewis S; Britton J
Clin Exp Allergy; 1997 May; 27(5):546-51. PubMed ID: 9179429
[TBL] [Abstract][Full Text] [Related]
15. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.
Norris V; Choong L; Tran D; Corden Z; Boyce M; Arshad H; Holgate S; O'Connor B; Millet S; Miller B; Rohatagi S; Kirkesseli S
J Allergy Clin Immunol; 2005 Oct; 116(4):761-7. PubMed ID: 16210048
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial.
Berger WE; Milgrom H; Skoner DP; Tripp K; Parsey MV; Baumgartner RA;
Curr Med Res Opin; 2006 Jun; 22(6):1217-26. PubMed ID: 16846555
[TBL] [Abstract][Full Text] [Related]
17. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
den Otter JJ; van Schayck CP; Folgering HT; van den Boom G; Akkermans RP; van Weel C
Eur J Gen Pract; 2007; 13(2):89-91. PubMed ID: 17534745
[TBL] [Abstract][Full Text] [Related]
18. Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler.
Goldberg J; Freund E; Beckers B; Hinzmann R
Eur Respir J; 2001 Feb; 17(2):225-32. PubMed ID: 11334124
[TBL] [Abstract][Full Text] [Related]
19. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
Kässner F; Hodder R; Bateman ED
Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
[TBL] [Abstract][Full Text] [Related]
20. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
